Elvitegravir is an integrase strand transfer inhibitor (INSTI) used in combination therapy to treat HIV-1 infection by blocking the viral enzyme responsible for integrating viral DNA into host genomic… Read more









































Elvitegravir is an integrase strand transfer inhibitor (INSTI) used in combination therapy to treat HIV-1 infection by blocking the viral enzyme responsible for integrating viral DNA into host genomic DNA. Analytical laboratories utilize high-quality reference standards for Elvitegravir, including process-related impurities, degradation products, metabolites, and stable isotope labelled compounds, to ensure rigorous quality control and safety compliance. These materials are essential for method development and validation, enabling precise impurity profiling and the accurate identification and quantification of analytes through techniques such as HPLC and LC-MS. Furthermore, stable isotope labelled standards serve as critical internal references in bioanalytical assays to enhance the reliability of pharmacokinetic studies. By providing fully characterized benchmarks, these compounds support researchers in maintaining adherence to international regulatory guidelines for drug safety, efficacy, and stability throughout the pharmaceutical development lifecycle.